Table 3.

Overview of selected neoadjuvant trials in MIBC testing chemo-immuntherapy combinations.

Chemo-immunotherapy combinations
Drugs	Number of patients	Study design	Primary endpoint	Status	Trial ID
Nivolumab + GC	43	Phase II Open Label Single arm	pCR rate	Has results	NCT03294304 (BLTASST-1)
Nivolumab + GC	76	Phase II Open Label Single arm	pCR rate 2 years MFS	Active, not recruiting	NCT03558087
Pembrolizumab + GC	39	Phase II Open Label Single arm	pD rate (< pT2)	Active, not recruiting	NCT02690558
Pembrolizumab + GC or G	83	Phase I/II	Safety pMI-RR	Recruiting	NCT02365766
Avelumab vs. Avelumab + MVAC vs. Avelumab + CG vs. Avelumab + PaG	166	II Open Label Single arm	pCR rate	Recruiting	NCT03674424 (AURA)
Durvalumab + MVAC vs. Durvalumab + Tremelimumab + MVAC	120	I/II non-comparative, open-label	pCR rate	Recruiting	NCT03549715 (NEMIO)

ID, identification number; GC, gemcitabine, cisplatin; pCR, pathologic complete response; 2 yrs MFS: two years metastasis-free survival; pD, pathologic down-staging; G, gemcitabine; pMI-RR, pathologic muscle invasive response rate; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; PaG, paclitaxel, gemcitabine.